Overview

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Status:
Completed
Trial end date:
2022-08-03
Target enrollment:
Participant gender:
Summary
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects. To evaluate the safety of ASK120067 tablets or combination with rifampicin capsules or itraconazole capsules in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Treatments:
Itraconazole
Rifampin